Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport. - Wikidata - wikimedia - TriplyDB

Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport.

Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport.

http://www.wikidata.org/entity/Q38153196

about

A Synopsis of Clinical Pharmacokinetic Alterations in Advanced CKD Anti-microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways Role of multidrug resistance-associated protein 4 in the basolateral efflux of hepatically derived enalaprilat.Effects of chronic kidney disease on liver transport: quantitative intravital microscopy of fluorescein transport in the rat liver.Drug-drug interactions and acute kidney injury: caveat prescriptor Influence of kidney function on risk of supratherapeutic international normalized ratio-related hemorrhage in warfarin users: a prospective cohort study.An Enlarged Profile of Uremic Solutes.Pharmacokinetic and pharmacodynamic considerations of antimicrobial drug therapy in cancer patients with kidney dysfunction Effect of Kidney Function on Drug Kinetics and Dosing in Neonates, Infants, and Children Onco-nephrology: an appraisal of the cancer and chronic kidney disease links.Influence of chronic kidney disease and haemodialysis treatment on pharmacokinetics of nebivolol enantiomers The Promises of Quantitative Proteomics in Precision Medicine Chronic Kidney Disease Alters Vitamin A Homeostasis via Effects on Hepatic RBP4 Protein Expression and Metabolic Enzymes.Consequences of renal failure on non-renal clearance of drugs.Kidney function assessment and its role in drug development, review and utilization.Pharmacokinetic considerations in chronic kidney disease and patients requiring dialysis.Emerging areas of research in the assessment of pharmacokinetics in patients with chronic kidney disease.Impact of physiological, pathological and environmental factors on the expression and activity of human cytochrome P450 2D6 and implications in precision medicine.PBPK Modeling of the Effect of Reduced Kidney Function on the Pharmacokinetics of Drugs Excreted Renally by Organic Anion Transporters.Perspective: 4β-hydroxycholesterol as an emerging endogenous biomarker of hepatic CYP3A.Importance of Hepatic Transporters in Clinical Disposition of Drugs and Their Metabolites.Update and trends on pharmacokinetic studies in patients with impaired renal function: practical insight into application of the FDA and EMA guidelines.Intermittent dosing of aromatase inhibitors (AI) to improve tolerance in postmenopausal women: a rationale for future clinical studies.The Pharmacokinetics of Beraprost Sodium Following Single Oral Administration to Subjects With Impaired Kidney Function.Systematic and quantitative assessment of the effect of chronic kidney disease on CYP2D6 and CYP3A4/5.Pharmacokinetics and safety of letermovir, a novel anti-human cytomegalovirus drug, in patients with renal impairment.Phenotyping and genotyping of CYP2C19 using comparative metabolism of proguanil in sickle-cell disease patients and healthy controls in Nigeria.Pharmacogenetics and precision medicine: Is inflammation a covert threat to effective genotype-based therapy?Pharmacotherapeutic considerations for chronic pain in chronic kidney and end-stage renal disease An empirical study of a hybrid imbalanced-class DT-RST classification procedure to elucidate therapeutic effects in uremia patients.Effect of Chronic Kidney Disease on Nonrenal Elimination Pathways: A Systematic Assessment of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and OATP.Effect of cardiopulmonary bypass on cytochrome P450 enzyme activity: implications for pharmacotherapy.Inhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxins.Indoxyl Sulfate Upregulates Liver P-Glycoprotein Expression and Activity through Aryl Hydrocarbon Receptor Signaling.Microbiota-derived uremic retention solutes: perpetrators of altered nonrenal drug clearance in kidney disease.Interactions of crizotinib and gefitinib with organic anion-transporting polypeptides (OATP)1B1, OATP1B3 and OATP2B1: gefitinib shows contradictory interaction with OATP1B3.The Role of the Kidney in Drug Elimination: Transport, Metabolism, and the Impact of Kidney Disease on Drug Clearance.Inflammation down-regulates CYP3A4-catalysed drug metabolism in hemodialysis patients.

P2860

Q28087621-97B7A419-B81A-41AA-8B0A-26B8DD394252 Q30405346-BFCF7571-0DE3-48BD-88ED-94EFF0C126BD Q34125053-B0AA829C-B93B-49E4-B35A-F360EACC2E64 Q34726696-1DECE624-0837-45B4-B039-A27CF79698D5 Q35339955-83610B5A-F70B-4C51-817B-50F772F994BC Q35553851-B4D4A0C7-A05F-4CD3-A219-4D5847763CD7 Q35759240-B0E9BBBA-3809-4933-B5C9-2769B31BE955 Q35819409-2D8C25FB-613B-4E9F-9B4F-257AEBBF923A Q36322918-5421532E-8BC7-425A-9FFE-EBE073173D54 Q36801561-31E1586D-43AF-4990-970E-1111307693A0 Q37030741-EA2D5B78-1EF2-4F15-BDE2-B7C0DB7A9E50 Q37647264-A6FCD258-C786-4458-A1B9-38D439152D4D Q37701154-5A36ACD8-5174-4B5C-8A26-01C78D2B3002 Q38214827-578BEEA6-CE96-4AC6-A3F7-8B90C56329BD Q38215907-D9B0ABFA-6612-47F3-A158-9CD2602F0C9A Q38222867-455DB819-2FF3-469D-A1C7-4B466514BC2A Q38287050-4648C9D2-8B7E-49A0-AB90-DB1ED976E77C Q38634986-93EB5DBE-E295-43B4-A4B9-C3B3F51056E4 Q38664509-F7441098-55FE-456E-BFD7-6A826F543772 Q38813488-50D9F6E7-23F8-4546-87A0-06A52C4785E3 Q38888365-7AEAF732-E9FA-4603-B8E3-377A91C18CF2 Q39044774-655F5659-2767-437C-8614-1586896C013C Q39044962-655A5139-E417-4D09-B43F-A407E8DADB40 Q39342998-95ED825C-863F-4878-B0CE-17B14EB98C36 Q40072776-38A8F5BC-0DC1-435C-94FA-63163B5E4033 Q40272806-0B9A752E-E9F5-4343-9FAA-81CEAAC0E915 Q41265929-2F275648-5ECB-4B55-9A22-2126444D4EF5 Q42345777-BD4F26E7-745F-4591-906F-833B17BF5143 Q42353634-B61F6B9A-CEEC-4E73-97B4-43455BC1B974 Q44592894-B53D356F-B5FC-4086-941A-2410427B9EDC Q46675919-83EDE712-D3CE-433D-9910-8DBD125ABD32 Q47288317-BF0854BF-3A78-4A5B-9707-B062F33B025A Q47853973-233C3231-DA14-4284-9E05-928637CE009A Q48150663-AE19858D-3CC3-4A46-8160-0D126008F1D0 Q50108575-F959DC68-11E1-43DE-B9C4-D0BE85657CD9 Q51069180-EB9D0594-1012-4ABC-8A2A-6D04B76D80F4 Q53233045-3968D44A-B041-4CA2-AB57-A8AD1B25CFCB Q55439721-D9E77644-7831-4875-BAD7-6A94D3A487CA

P2860

Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport.

http://www.wikidata.org/entity/Q38153196

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport.

@en

type

label

Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport.

@en

prefLabel

Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport.

@en

P1433

Q38153196-52C83D55-6BA7-438B-833B-377172FF3E0C

P1476

Q38153196-86049816-8FAB-4BFE-80B5-65A54EA33138

P2093

Q38153196-A104CFEF-EF3F-4790-AFFE-7A3CF044B7B8

Q38153196-A420048E-7B3E-4355-B93F-D3AF21307057

Q38153196-DD17DE80-02B5-40E1-BA3F-FABF39525AF4

Q38153196-FF2929A9-9FAC-4412-A6E3-549F1FC0DA93

P2860

Q38153196-001F430A-2865-437C-80EF-05B444DB3D2F

Q38153196-17E62E30-E918-4DCC-8807-1FC50EC52930

Q38153196-1F09E256-F725-472B-99FE-351014F958CB

Q38153196-26DB99EB-C6AA-4AFF-B86B-B213D0BC7953

Q38153196-2BF27298-8F20-4091-964F-FB707552FE5D

Q38153196-2EC19343-59F7-4C62-BF42-1AD18688CA9C

Q38153196-2F1D074B-1CF1-42FF-8BE7-FFA075304678

Q38153196-2F6E1918-7E1F-4C52-9152-555ABB688005

Q38153196-30E1FA13-5EDE-4886-A822-9551DAC748A4

Q38153196-328CE223-E8E4-4DF4-9715-50F05B7F3F34

P2888

Q38153196-AD6EC9E1-1DFD-4662-AF78-EC364EB8AB2B

P304

Q38153196-498D6612-5DE2-4CE2-9E0F-195BD77F8E84

P31

Q38153196-6E3171DC-8E47-4071-A83E-7E1679F6002D

Q38153196-CFE7927F-0607-458E-B206-7D0DEA18122D

P356

Q38153196-FD53BF3B-7953-4F1B-8045-D7B2606D3378

P407

Q38153196-D7C98542-2388-4DF9-8C9D-E742F6B68231

P433

Q38153196-C41EE477-9D84-4229-8132-E31FF40A089A

P478

Q38153196-905724F0-BDEB-45BB-AB0D-1E294DDFC64A

P577

Q38153196-5BDACB76-6764-4771-A847-579E99764485

Q38153196-FE8A55F3-061C-439B-9AFE-40DF025AEDFC

P5875

Q38153196-B4BF6E5A-E0A8-42DC-9686-03CF78A3447A

P6179

Q38153196-D3E47FBD-1E25-4ED8-B304-3E5E2F758EA6

P698

Q38153196-5F40945E-9BC9-4A1B-9BB6-DA31AB7A053B

P921

Q38153196-35C6C9FB-8C35-4F51-94E9-294351DB4CC4

Q38153196-5F244102-1C49-4C1D-A156-32CDC565AE34

Q38153196-A14289DD-DC46-4098-A232-8E1701455449

Q38153196-CA055B88-8096-4591-8C3E-6D94594D7BCE

P932

Q38153196-46391550-AF83-4986-A3B7-29E9CDF07711

P356

P1433

Kidney International

P1476

Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport.

@en

P2093

Catherine K Yeung

http://www.w3.org/2001/XMLSchema#string

Danny D Shen

http://www.w3.org/2001/XMLSchema#string

Jonathan Himmelfarb

http://www.w3.org/2001/XMLSchema#string

Kenneth E Thummel

http://www.w3.org/2001/XMLSchema#string

P2860

Immunoquantitation of FMO1 in human liver, kidney, and intestine

The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution

Prevalence of chronic kidney disease in the United States

In vitro microvessels for the study of angiogenesis and thrombosis.

The effect of chronic renal failure on hepatic drug metabolism and drug disposition.

Downregulation of hepatic cytochrome P450 in chronic renal failure.

Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions.

Heterotropic cooperativity of cytochrome P450 3A4 and potential drug-drug interactions.

Effects of serum from patients with chronic renal failure on rat hepatic cytochrome P450

Review on uremic toxins: classification, concentration, and interindividual variability.

P2888

P304

522-528

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/KI.2013.399

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

85

http://www.w3.org/2001/XMLSchema#string

P577

2013-10-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2014-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

257888712

http://www.w3.org/2001/XMLSchema#string

P6179

1014691736

http://www.w3.org/2001/XMLSchema#string

P698

24132209

http://www.w3.org/2001/XMLSchema#string

P921

pharmaceutical preparation

chronic kidney disease

P932

4276411

http://www.w3.org/2001/XMLSchema#string